Tuesday, January 05, 2021 9:43:42 AM
Average: $26.17
Average after discarding top 10% & bottom 10%: $24.48
Median: $24.00
Everyone has until January 8, 2021 to add or amend their prediction and then I will retire this until December 31, 2021, or sooner if needed wink
4.89 Tal10
5.25 hoggydog
5.30 wodehouse
6.00 shakyman
6.66 Abe1234
7.25 Amarin_Buyout
7.50 MNBioMike
7.75 BioBS2012
9.00 newtotheparty
9.75 The Canes
10.50 mrmainstreet
10.50 lizzy241
11.00 DKNY1
12.00 berryfitRD
12.75 Crikker
13.00 shadolane
13.00 Babr
13.00 hamkypamky
14.99 TastyTheElf
15.00 Jimcal22
15.00 Retired2019
16.00 Megc
16.00 dukesking
16.00 Invest83838
16.00 heysfguy
16.90 studythosestocks
17.00 Rafunrafun
17.50 Notademoc
18.00 lorbas95
18.50 DD222
18.50 Hey Jakey
18.50 kjones3701
19.00 DirteeHarree
20.00 tm100
21.56 Realcool11
22.00 juslin
22.00 alm2
22.00 momoney24
22.50 oneragman
23.00 Bolio98
23.45 Toddrobertking
23.50 mag6898
24.00 Lemmiwinks
24.00 Examiner77
24.30 louieblouie
24.75 best golfer
24.95 hankbb02
25.00 Chemist2
25.00 Irish guy 009
25.00 USAFC130
25.00 Gbert
26.00 alwayswatching1
26.00 Downtownguy
26.00 CaptBeer
26.50 rydad21
26.69 luvbio
27.55 Martinko
28.50 FesteringPus
30.00 money_man
30.00 BrunoGOudega
30.00 FlyFishingStocks
32.00 Glycol
32.50 DAR53
35.00 Retiredceo
35.00 BioBull
35.00 MA52TA
35.00 Bluensleepy
35.00 xblkbk
35.00 Number sleven
36.66 invest2992
36.81 grbnitz4002 (1 $PFE)
40.00 north40000
43.00 Vegas8ball
43.75 bidmark
44.00 Monk44
44.00 Pterion
44.00 NI- bound
45.00 noelan_s09
47.00 ORBAPU
50.00 golf stud
50.00 iryokabu
52.00 creynolds
52.00 finh
55.00 jasbg
66.00 Freifaller
110.00 Biobillionair
Recent AMRN News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM